Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00405964 | Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684) | PHASE3 | COMPLETED | 716 | — | — | Sep 1, 2006 | Apr 1, 2008 | May 20, 2024 | - | — |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference.
| Arm | Type | Description |
|---|---|---|
| 5-mg Desloratadine tablet | EXPERIMENTAL | - |
| Placebo tablet | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 5-mg Desloratadine | DRUG | 5-mg Desloratadine tablet, once daily for 12 weeks |
| Placebo tablet | DRUG | Placebo tablet, once daily for 12 weeks |
Inclusion Criteria: * For this study, the diagnosis of persistent allergic rhinitis (PER) is not based solely on the current episode of allergic rhinitis (AR). Subjects must have at least a 2 year history of AR consistent with PER (defined as symptoms of allergic rhinitis present more than four day...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |